WEREWOLF THERAPEUTICS INC
HOWLNASDAQTrading Snapshot
- Day Range
- $0.93 β $0.99
- 52-Week Range
- $0.27 β $1.20
- Volume (shares)
- 374,029
- Avg Volume (shares)
- β
- Shares Outstanding
- 48.6M
- Next Earnings
- 2027-03-25
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- $21M
- P/E Ratio
- -1.6
- P/S Ratio
- 2.2x
- EPS (TTM)
- $-0.58
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +5.2%
WEREWOLF THERAPEUTICS INC
HOWLAbout WEREWOLF THERAPEUTICS INC
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
βLatest News & Updates

Werewolf Therapeutics' Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer's (SITC) 2026 Annual Meeting
WALTHAM, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the βCompanyβ or βWerewolfβ) (Nasdaq: HOWL), a biopharmaceutical company that has developed conditionally activated therapeutics engineered t

Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 2026 Annual Meeting
WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the βCompanyβ or βWerewolfβ) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated th

Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why
Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

New Strong Buy Stocks for October 9th
LITE, HOWL, PERI, GSBD and GFF have been added to the Zacks Rank #1 (Strong Buy) List on October 9th, 2026.

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Stock Has Average Target Price of $4.00 According to Analysts
Shares of Werewolf Therapeutics, Inc. (NASDAQ: HOWL - Get Free Report) have been assigned an average rating of "Hold" from the seven ratings firms that are currently covering the stock, Marketbeat.com reports. One resear

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq β HOWL), Beazer Homes USA, Inc. (NYSE β BZH), Lantheus Holdings Inc. (Nasdaq β LNTH), MarketAxess Holdings Inc. (Nasdaq β MKTX)
BALA CYNWYD, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmit